{"preliminary_commentary":{"by_channel":{"x_thread":12,"youtube":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05340374\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"LuCAB","nct_id":"NCT05340374","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=lucab-nct05340374. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"LuCAB","arms":[{"description":"In this single-arm study, patients will receive 7.4 GBq of 177Lu-PSMA-617 on Day 1 of every 6 week Cycle. Cabazitaxel will be administered concurrently on Day 2 and Day 23 of each Cycle (every 3 weeks). The dose of cabazitaxel will vary in dose-escalation. Up to 6 Cycles will be given.","label":"Treatment Arm","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-12","type":"ESTIMATED"},"conditions":["Metastatic Castration-resistant Prostate Cancer","mCRPC"],"enrollment":{"count":35,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Cabazitaxel","otherNames":[],"type":"DRUG"},{"name":"177Lu-PSMA-617","otherNames":[],"type":"DRUG"}],"last_update":"2025-04-06","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","official_title":"Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2026-06-20","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of participants with Dose Limiting Toxicities (DLTs)","timeFrame":"Dose escalation phase is expected to be completed 9 months from the time the first patient is recruited."},{"measure":"Maximum Tolerated dose (MTD)","timeFrame":"Dose escalation phase is expected to be completed 9 months from the time the first patient is recruited."},{"measure":"Recommended Phase 2 Dose (RP2D)","timeFrame":"Up to 30 months from the time the first patient is recruited."}],"references":[{"citation":"Kostos L, Buteau JP, Kong G, Tran B, Haskali MB, Fahey M, Crumbaker M, Emmett L, Hofman MS, Azad AA. Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2025 Apr 1;66(4):572-578. doi: 10.2967/jnumed.124.269252.","pmid":"39978808","type":"DERIVED"}],"start_date":{"date":"2022-07-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT05340374"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/lucab-nct05340374"}